These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25105184)

  • 21. Dalbavancin or oritavancin for skin infections.
    Boucher HW; Talbot GH; Dunne MW
    N Engl J Med; 2014 Sep; 371(12):1161-2. PubMed ID: 25229922
    [No Abstract]   [Full Text] [Related]  

  • 22. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delafloxacin: First Global Approval.
    Markham A
    Drugs; 2017 Sep; 77(13):1481-1486. PubMed ID: 28748399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults.
    Zervou FN; Zacharioudakis IM; Mylonakis E
    Ann Intern Med; 2014 Oct; 161(8):JC9. PubMed ID: 25329226
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA approves first drug in new class of antibiotics.
    Senior K
    Lancet; 2000 Apr; 355(9214):1523. PubMed ID: 10801180
    [No Abstract]   [Full Text] [Related]  

  • 27. Bacterial skin infections: unapproved treatments.
    Sadick NS
    Clin Dermatol; 2002; 20(6):613-7. PubMed ID: 12490353
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 29. Antimicrobial agents for complicated skin and skin-structure infections: noninferiority margins, placebo-controlled trials, and the complexity of clinical trials.
    Stevens DL
    Clin Infect Dis; 2009 Aug; 49(3):392-4. PubMed ID: 19555284
    [No Abstract]   [Full Text] [Related]  

  • 30. Stewarding the Costly Antibiotic: Considerations for Dalbavancin.
    Bookstaver PB; Milgrom A
    Clin Infect Dis; 2021 Oct; 73(7):e1443-e1444. PubMed ID: 33211844
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.
    Itani KM; Shorr AF
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S4-9. PubMed ID: 24343831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA approves new antibiotic combination for drug-resistant pneumonia.
    Mullard A
    Nat Rev Drug Discov; 2023 Jul; 22(7):527. PubMed ID: 37286780
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA approves Cimzia to treat Crohn's disease.
    Lang L
    Gastroenterology; 2008 Jun; 134(7):1819. PubMed ID: 18474249
    [No Abstract]   [Full Text] [Related]  

  • 34. New drugs 2015, part 2.
    Hussar DA
    Nursing; 2015 Jul; 45(7):34-41; quiz 41-2. PubMed ID: 26083291
    [No Abstract]   [Full Text] [Related]  

  • 35. Antimicrobial agents in treatment of MRSA infections.
    Johnson MD; Decker CF
    Dis Mon; 2008 Dec; 54(12):793-800. PubMed ID: 18996282
    [No Abstract]   [Full Text] [Related]  

  • 36. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infectious disease update: new anti-microbials.
    Yang A; Kerdel FA
    Semin Cutan Med Surg; 2006 Jun; 25(2):94-9. PubMed ID: 16908400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftaroline: a comprehensive update.
    Kaushik D; Rathi S; Jain A
    Int J Antimicrob Agents; 2011 May; 37(5):389-95. PubMed ID: 21420284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA approves new drug to treat dementia.
    J Gerontol Nurs; 2015 Mar; 41(3):5. PubMed ID: 25710261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.